Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Pancreatic Cancer |
Dose: Intravenous – 125 mg/m² Frequency: once daily on Days 1, 8 and 15 of each 28-day cycle Note: Infused over 30-40 minutes. Indicated for metastatic adenocarcinoma of the pancreas as first-line treatment in combination with gemcitabine. Administer gemcitabine 1000 mg/m² intravenously infused over 30-40 minutes immediately after paclitaxel protein bound on Days 1, 8 and 15 of each 28-day cycle. |
|
Indication: Pancreatic Cancer Condition: First dose reduction |
Dose: Intravenous – 100 mg/m² Frequency: once daily on Days 1, 8 and 15 of each 28-day cycle Note: Concurrently reduce gemcitabine dose to 800 mg/m². Discontinue if additional dose reduction required past the second dose reduction level. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: No approved pediatric dosage available Note: No approved pediatric dosage available |
Administration
- Given as IV infusion
- Must be administered by healthcare professionals
Side Effect
- Alopecia (90%)
- Neutropenia (Less than 2 x 10^9/L) (80%)
- Sensory neuropathy, any (71%)
- Abnormal EKG
- all patients (60%)
- Asthenia (47%)
- Myalgia/arthralgia (44%)
- AST increased (39%)
- Alkaline phosphatase increased (36%)
- Abnormal EKG
- patients normal at baseline (35%)
- Anemia (Less than 11 g/dL) (33%)
- Nausea (30%)
- Diarrhea (27%)
- Infections (24%)
- Vomiting (18%)
- Dyspnea (12%)
- Neutropenia (grade 3-4)
- NSCLC (47%)
- Pancreatic cancer (38%)
- Metastatic breast cancer (34%)
- Sensory neuropathy, severe (10%)
- Edema (10%)
- Neutropenia (Less than 0.5 x 10^9/L) (9%)
- Cough (7%)
- Mucositis (7%)
- Bilirubin increased (7%)
- Hypotension, during infusion (5%)
- Hypersensitivity reactions (4%)
- Thrombocytopenia (2%)
- Febrile neutropenia (2%)
- Bleeding (2%)
- Anemia (Less than 8 g/dL) (1%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
No interactions listed
|
-
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Neutrophils <1500 cells/mm³
|
High risk of infection
|
|
Severe Hypersensitivity
|
Risk of anaphylactic shock
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store the vials in original cartons at 20°C to 25°C. Retain in the original package to protect from bright light.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.